{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:12:59Z","timestamp":1788358379257,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["77380"],"award-info":[{"award-number":["77380"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12426-1","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:15:58Z","timestamp":1788354958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated roles of miR-125b, miR-375, and miR-451 in breast cancer chemoresistance: mechanistic insights and translational implications"],"prefix":"10.1007","volume":"53","author":[{"given":"Danial","family":"Ahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Rashtchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solmaz","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Shekari","family":"Khaniani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima Mansoori","family":"Derakhshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"3","key":"12426_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","volume":"2","author":"TJ Key","year":"2001","unstructured":"Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2(3):133\u2013140","journal-title":"Lancet Oncol"},{"issue":"4","key":"12426_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","volume":"35","author":"MPA Nikolaou","year":"2018","unstructured":"Nikolaou MPA, Georgakilas AG, Kyrodimos E (2018) The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis 35(4):309\u2013318","journal-title":"Clin Exp Metastasis"},{"issue":"21","key":"12426_CR3","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.3390\/cancers13215350","volume":"13","author":"HER Shaath","year":"2021","unstructured":"Shaath HER, Alajez NM (2021) Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer. Cancers 13(21):5350","journal-title":"Cancers"},{"issue":"2","key":"12426_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281\u2013297","journal-title":"Cell"},{"issue":"5","key":"12426_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","volume":"75","author":"BHI Wightman","year":"1993","unstructured":"Wightman BHI, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75(5):855\u2013862","journal-title":"Cell"},{"issue":"18","key":"12426_CR6","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/eurheartj\/ehx204","volume":"38","author":"M Nicholls","year":"2017","unstructured":"Nicholls M (2017) MicroRNA biomarkers. Eur Heart J 38(18):1358\u20131359","journal-title":"Eur Heart J"},{"key":"12426_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/BCTT.S43799","volume":"7","author":"CR Graveel","year":"2015","unstructured":"Graveel CR, Calderone HM, Westerhuis JJ, Winn ME, Sempere LF (2015) Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer: Targets Therapy 7:59\u201379. https:\/\/doi.org\/10.2147\/BCTT.S43799","journal-title":"Breast Cancer: Targets Therapy"},{"issue":"6","key":"12426_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.molmed.2011.01.006","volume":"17","author":"CANB Andorfer","year":"2011","unstructured":"Andorfer CANB, Thompson EA, Perez EA (2011) MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 17(6):313\u2013319","journal-title":"Trends Mol Med"},{"issue":"1","key":"12426_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.21873\/anticanres.17926","volume":"46","author":"CJTS Chang","year":"2026","unstructured":"Chang CJTS, Liao WT, Lay IS, Chiang CC, Tseng YW et al (2026) THEMIS2 as a Novel Mediator of VEGFR2-driven Angiogenesis in Breast Cancer: Functional Suppression by miR-125b-5p. Anticancer Res 46(1):95\u2013111","journal-title":"Anticancer Res"},{"issue":"2","key":"12426_CR10","first-page":"1621","volume":"15","author":"GZX Hu","year":"2018","unstructured":"Hu GZX, Wang J, Lv L, Wang C, Feng L et al (2018) miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1. Oncol Lett 15(2):1621\u20131629","journal-title":"Oncol Lett"},{"key":"12426_CR11","doi-asserted-by":"crossref","unstructured":"Jayaraj R, Nayagam SG, Kar A, Sathyakumar S, Mohammed H, Smiti M et al (2019) Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis. Cells. ;8(10)","DOI":"10.3390\/cells8101250"},{"issue":"5","key":"12426_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ijc.28563","volume":"135","author":"J-W Yan","year":"2014","unstructured":"Yan J-W, Lin J-S, He X-X (2014) The emerging role of miR-375 in cancer. Int J Cancer 135(5):1011\u20131018","journal-title":"Int J Cancer"},{"issue":"1","key":"12426_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41467-019-08989-2","volume":"10","author":"A-C Frank","year":"2019","unstructured":"Frank A-C, Ebersberger S, Fink AF, Lampe S, Weigert A, Schmid T et al (2019) Apoptotic tumor cell-derived microRNA-375 uses CD36 to alter the tumor-associated macrophage phenotype. Nat Commun 10(1):1135","journal-title":"Nat Commun"},{"key":"12426_CR14","doi-asserted-by":"publisher","unstructured":"de Souza Rocha Simonini PBA, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, Diederichs S, Sahin O, Mayer D, Lyko F, Hoheisel JD, Riazalhosseini Y (2010) Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 70(22):9175\u20139184.https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1318 Epub 2010 Oct 26. PMID: 20978187","DOI":"10.1158\/0008-5472.CAN-10-1318"},{"issue":"3\u20134","key":"12426_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13353-019-00507-w","volume":"60","author":"JWP Liu","year":"2019","unstructured":"Liu JWP, Zhang P, Zhang X, Du H, Liu Q, Huang B, Qian C, Zhang S, Zhu W, Yang X, Xiao Y, Liu Z, Luo D (2019) An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer. J Appl Genet 60(3\u20134):335\u2013346. https:\/\/doi.org\/10.1007\/s13353-019-00507-w Epub 2019 Aug 1. PMID: 31372832","journal-title":"J Appl Genet"},{"issue":"2","key":"12426_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3892\/or.2017.5360","volume":"37","author":"H Fu","year":"2017","unstructured":"Fu H, Fu L, Xie C, Zuo W-S, Liu Y-S, Zheng M-Z et al (2017) miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. Oncol Rep 37(2):1093\u20131099","journal-title":"Oncol Rep"},{"issue":"13","key":"12426_CR17","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00018-015-1887-1","volume":"72","author":"W Zhang","year":"2015","unstructured":"Zhang W, Xu J, Shi Y, Sun Q, Zhang Q, Guan X (2015) The novel role of miRNAs for tamoxifen resistance in human breast cancer. Cell Mol Life Sci 72(13):2575\u20132584","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"12426_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/onc.2012.128","volume":"32","author":"A Ward","year":"2013","unstructured":"Ward A, Balwierz A, Zhang JD, K\u00fcblbeck M, Pawitan Y, Hielscher T et al (2013) Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 32(9):1173\u20131182","journal-title":"Oncogene"},{"key":"12426_CR19","doi-asserted-by":"crossref","unstructured":"Santana MFM, Sawada M, Santos AS, Reis M, Xavier J, C\u00f4rrea-Giannella ML et al (2023) Increased Expression of miR-223-3p and miR-375-3p and Anti-Inflammatory Activity in HDL of Newly Diagnosed Women in Advanced Stages of Breast Cancer. Int J Mol Sci. ;24(16)","DOI":"10.3390\/ijms241612762"},{"issue":"12","key":"12426_CR20","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1172\/JCI91553","volume":"127","author":"S Wang","year":"2017","unstructured":"Wang S, Liang K, Hu Q, Li P, Song J, Yang Y et al (2017) JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest 127(12):4498\u20134515","journal-title":"J Clin Invest"},{"issue":"7","key":"12426_CR21","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1172\/JCI44745","volume":"121","author":"LL Marotta","year":"2011","unstructured":"Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR et al (2011) The JAK2\/STAT3 signaling pathway is required for growth of CD44\u207aCD24\u207b stem cell-like breast cancer cells in human tumors. J Clin Invest 121(7):2723\u20132735","journal-title":"J Clin Invest"},{"issue":"24","key":"12426_CR22","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1039\/D4NA00660G","volume":"6","author":"APK Verma","year":"2024","unstructured":"Verma APK, Kumar A (2024) Targeting drug resistance in breast cancer: the potential of miRNA and nanotechnology-driven delivery systems. Nanoscale Adv 6(24):6079\u20136095","journal-title":"Nanoscale Adv"},{"issue":"1","key":"12426_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2407-14-134","volume":"14","author":"X-M Ye","year":"2014","unstructured":"Ye X-M, Zhu H-Y, Bai W-D, Wang T, Wang L, Chen Y et al (2014) Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer 14(1):134","journal-title":"BMC Cancer"},{"issue":"1","key":"12426_CR24","first-page":"27","volume":"31","author":"YELW Xingming","year":"2021","unstructured":"Xingming YELW, Jing JI, Xiufeng WU, Ying CH (2021) miR-375 targeting YAP1 modulates trastuzumab resistance through epithelial-mesenchymal transition in breast cancer cells. China Oncol 31(1):27\u201334","journal-title":"China Oncol"},{"issue":"15","key":"12426_CR25","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.3390\/cancers13153691","volume":"13","author":"G Cosentino","year":"2021","unstructured":"Cosentino G, Plantamura I, Tagliabue E, Iorio MV, Cataldo A (2021) Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. Cancers 13(15):3691","journal-title":"Cancers"},{"issue":"10","key":"12426_CR26","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/medicina58101494","volume":"58","author":"LARA Lisencu","year":"2022","unstructured":"Lisencu LARA, Visan S, Bonci EA, Pa\u0219ca A, Grigorescu E, Mustea E, Cismaru A, Irimie A, Lisencu C, Balacescu L (2022) The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the pathological response of breast cancer patients to neoadjuvant therapy. Medicina 58(10):1494","journal-title":"Medicina"},{"issue":"1","key":"12426_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ijc.29985","volume":"139","author":"M-C Casey","year":"2016","unstructured":"Casey M-C, Sweeney KJ, Brown JAL, Kerin MJ (2016) Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer 139(1):12\u201322","journal-title":"Int J Cancer"},{"issue":"4","key":"12426_CR28","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s12010-013-0633-0","volume":"172","author":"FHM Kouhkan","year":"2014","unstructured":"Kouhkan FHM, Mobarra N, Mossahebi-Mohammadi M, Mohammadi S, Behmanesh M, Soufi Zomorrod M, Alizadeh S, Lahmy R, Daliri M, Soleimani M (2014) miRNAs: a new method for erythroid differentiation of hematopoietic stem cells without the presence of growth factors. Appl Biochem Biotechnol 172(4):2055\u20132069","journal-title":"Appl Biochem Biotechnol"},{"key":"12426_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2014.00475","volume":"5","author":"BDG Alural","year":"2014","unstructured":"Alural BDG, Tufekci KU, Allmer J, Onkal Z, Tunali D, Genc K, Genc S (2014) EPO mediates neurotrophic, neuroprotective, anti-oxidant, and anti-apoptotic effects via downregulation of miR-451 and miR-885-5p in SH-SY5Y neuron-like cells. Front Immunol 5:475","journal-title":"Front Immunol"},{"key":"12426_CR30","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.2147\/OTT.S230963","volume":"12","author":"H Bai","year":"2019","unstructured":"Bai H, Wu S (2019) miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer. OncoTargets Therapy 12:11069\u201311082. https:\/\/doi.org\/10.2147\/OTT.S230963","journal-title":"OncoTargets Therapy"},{"issue":"2","key":"12426_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.canlet.2011.07.026","volume":"311","author":"XCTL Wang","year":"2011","unstructured":"Wang XCTL, Jiang XY, Wang YY, Li DG, She Y, Chang JH, Meng AM (2011) The expression and function of miRNA-451 in non-small cell lung cancer. Cancer Lett 311(2):203\u2013209.https:\/\/doi.org\/10.1016\/j.canlet.2011.07.026 Epub 2011 Aug 10. PMID: 21875770","journal-title":"Cancer Lett"},{"key":"12426_CR32","doi-asserted-by":"publisher","unstructured":"Bitarte NBE, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM, Fortes P, Garcia-Foncillas J (2011) MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. ;29(11):1661-71. https:\/\/doi.org\/10.1002\/stem.741. PMID: 21948564","DOI":"10.1002\/stem.741"},{"issue":"10","key":"12426_CR33","doi-asserted-by":"publisher","first-page":"13751","DOI":"10.1007\/s13277-016-5219-3","volume":"37","author":"HNY Guo","year":"2016","unstructured":"Guo HNY, Zhen Y, Zhang Y, Guo L, Yu K, Huang Q, Zhong Y (2016) miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1. Tumour Biol 37(10):13751\u201313761. https:\/\/doi.org\/10.1007\/s13277-016-5219-3 Epub 2016 Jul 31. PMID: 27476171","journal-title":"Tumour Biol"},{"issue":"8","key":"12426_CR34","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/nar\/gki567","volume":"33","author":"YLP Altuvia","year":"2005","unstructured":"Altuvia YLP, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T, Margalit H (2005) Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 33(8):2697\u20132706","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"12426_CR35","first-page":"282","volume":"51","author":"ITG Astuti","year":"2019","unstructured":"Astuti ITG, Sa\u2019adah N, Oktriani R, Wardana T, Aryandono T, Mubarika S (2019) Resistance to doxorubicin correlated with dysregulation of microRNA-451 and P-glyoprotein, caspase 3, estrogen Receptor on Breast Cancer cell line. J Med Sci (Berkala Ilmu Kedokteran) 51(4):282\u2013291","journal-title":"J Med Sci (Berkala Ilmu Kedokteran)"},{"key":"12426_CR36","doi-asserted-by":"publisher","first-page":"1155254","DOI":"10.3389\/fonc.2023.1155254","volume":"13","author":"S Singh","year":"2023","unstructured":"Singh S, Saini H, Sharma A, Gupta S, Huddar VG, Tripathi R (2023) Breast cancer: miRNAs monitoring chemoresistance and systemic therapy. Front Oncol 13:1155254. https:\/\/doi.org\/10.3389\/fonc.2023.1155254","journal-title":"Front Oncol"},{"issue":"9","key":"12426_CR37","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.3390\/cancers12092698","volume":"12","author":"E-G Dobre","year":"2020","unstructured":"Dobre E-G, Dinescu S, Costache M (2020) Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer. Cancers 12(9):2698","journal-title":"Cancers"},{"issue":"7","key":"12426_CR38","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-08-0021","volume":"7","author":"O Kovalchuk","year":"2008","unstructured":"Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7(7):2152\u20132159","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"12426_CR39","doi-asserted-by":"publisher","first-page":"e3071","DOI":"10.1038\/cddis.2017.460","volume":"8","author":"W Wang","year":"2017","unstructured":"Wang W, Zhang L, Wang Y, Ding Y, Chen T, Wang Y et al (2017) Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis 8(10):e3071\u2013e","journal-title":"Cell Death Dis"},{"key":"12426_CR40","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.12659\/msm.894475","volume":"21","author":"X Gu","year":"2015","unstructured":"Gu X, Li JY, Guo J, Li PS, Zhang WH (2015) Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line. Med Sci monitor: Int Med J experimental Clin Res 21:3291\u20133297. https:\/\/doi.org\/10.12659\/msm.894475","journal-title":"Med Sci monitor: Int Med J experimental Clin Res"},{"issue":"3","key":"12426_CR41","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.31557\/APJCP.2022.23.3.1053","volume":"23","author":"AA Abdul Aziz","year":"2022","unstructured":"Abdul Aziz AA, Md Salleh MS, Yahya MM, Zakaria AD, Ankathil R (2022) Down Regulated Expression Levels of miR-27b and miR-451a as a Potential Biomarker for Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy. Asian Pac J cancer prevention: APJCP 23(3):1053\u20131059. https:\/\/doi.org\/10.31557\/APJCP.2022.23.3.1053","journal-title":"Asian Pac J cancer prevention: APJCP"},{"key":"12426_CR42","doi-asserted-by":"publisher","first-page":"154702","DOI":"10.1016\/j.prp.2023.154702","volume":"249","author":"A Ebrahimi","year":"2023","unstructured":"Ebrahimi A, Bakhshaei Shahrebabaki P, Fouladi H, Mansoori Derakhshan S (2023) The impact of microRNAs on the resistance of breast cancer subtypes to chemotherapy. Pathol - Res Pract 249:154702","journal-title":"Pathol - Res Pract"},{"issue":"3","key":"12426_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/CBM-160578","volume":"16","author":"S-J Gu X XJ-Q, Han","year":"2016","unstructured":"1, Gu X XJ-Q, Han S-J, Qian S-Y, Zhang W-H (2016) Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. Cancer Biomarkers 16(3):395\u2013403. https:\/\/doi.org\/10.3233\/CBM-160578","journal-title":"Cancer Biomarkers"},{"key":"12426_CR44","doi-asserted-by":"publisher","unstructured":"1, Shao BWX, Zhang L et al (2019) Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Technol Cancer Res Treat 18. https:\/\/doi.org\/10.1177\/1533033819828709","DOI":"10.1177\/1533033819828709"},{"issue":"12","key":"12426_CR45","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3390\/biom14121580","volume":"14","author":"CBSB Patury","year":"2024","unstructured":"Patury CBSB, Matos AL, Slabi J, Gastalho LC, Kaneto CM (2024) Dysregulation of MiR-21, MiR-221 and MiR-451 During Neoadjuvant Treatment of Breast Cancer: A Prospective Study. Biomolecules 14(12):1580","journal-title":"Biomolecules"},{"key":"12426_CR46","doi-asserted-by":"publisher","first-page":"153303381982870","DOI":"10.1177\/1533033819828709","volume":"18","author":"BWX Shao","year":"2019","unstructured":"Shao BWX, Zhang L, Li D, Liu X, Song G et al (2019) Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Technol Cancer Res Treat 18:1533033819828709","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"12426_CR47","doi-asserted-by":"publisher","first-page":"e0152032","DOI":"10.1371\/journal.pone.0152032","volume":"11","author":"M Al-Khanbashi","year":"2016","unstructured":"Al-Khanbashi M, Caramuta S, Alajmi AM, Al-Haddabi I, Al-Riyami M, Lui W-O et al (2016) Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment. PLoS ONE 11(4):e0152032","journal-title":"PLoS ONE"},{"key":"12426_CR48","doi-asserted-by":"crossref","unstructured":"Chung J, Soung YH (2026) Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities. Biomolecules. ;16(5)","DOI":"10.3390\/biom16050682"},{"key":"12426_CR49","doi-asserted-by":"publisher","first-page":"1134779","DOI":"10.3389\/fgene.2023.1134779","volume":"14","author":"T Singh","year":"2023","unstructured":"Singh T, Kaushik M, Mishra LC, Behl C, Singh V, Tuli HS (2023) Exosomal miRNAs as novel avenues for breast cancer treatment. Front Genet 14:1134779","journal-title":"Front Genet"},{"issue":"6","key":"12426_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3892\/ol.2021.13080","volume":"22","author":"A Sueta","year":"2021","unstructured":"Sueta A, Fujiki Y, Goto-Yamaguchi L, Tomiguchi M, Yamamoto-Ibusuki M, Iwase H et al (2021) Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment. Oncol Lett 22(6):819","journal-title":"Oncol Lett"},{"issue":"9","key":"12426_CR51","doi-asserted-by":"publisher","first-page":"e24145","DOI":"10.1371\/journal.pone.0024145","volume":"6","author":"MB Kirschner","year":"2011","unstructured":"Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N et al (2011) Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE 6(9):e24145","journal-title":"PLoS ONE"},{"key":"12426_CR52","doi-asserted-by":"publisher","first-page":"731479","DOI":"10.1155\/2015\/731479","volume":"2015","author":"P Tiberio","year":"2015","unstructured":"Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V (2015) Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int 2015:731479","journal-title":"Biomed Res Int"},{"issue":"1","key":"12426_CR53","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ymeth.2012.09.015","volume":"59","author":"T Blondal","year":"2013","unstructured":"Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M et al (2013) Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59(1):S1\u20136","journal-title":"Methods"},{"issue":"6","key":"12426_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/clinchem\/hvaf043","volume":"71","author":"SA Bustin","year":"2025","unstructured":"Bustin SA, Ruijter JM, van den Hoff MJB, Kubista M, Pfaffl MW, Shipley GL et al (2025) MIQE 2.0: Revision of the Minimum Information for Publication of Quantitative Real-Time PCR Experiments Guidelines. Clin Chem 71(6):634\u2013651","journal-title":"Clin Chem"},{"key":"12426_CR55","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.bios.2015.07.048","volume":"74","author":"P Wang","year":"2015","unstructured":"Wang P, Jing F, Li G, Wu Z, Cheng Z, Zhang J et al (2015) Absolute quantification of lung cancer related microRNA by droplet digital PCR. Biosens Bioelectron 74:836\u2013842","journal-title":"Biosens Bioelectron"},{"issue":"5","key":"12426_CR56","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/bcr2943","volume":"13","author":"HN Appaiah","year":"2011","unstructured":"Appaiah HN, Goswami CP, Mina LA, Badve S, Sledge GW Jr., Liu Y et al (2011) Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res 13(5):R86","journal-title":"Breast Cancer Res"},{"issue":"9","key":"12426_CR57","doi-asserted-by":"publisher","first-page":"BSR20211494","DOI":"10.1042\/BSR20211494","volume":"41","author":"JLY Wei","year":"2021","unstructured":"Wei JLY, Wang R, Xu X, Liu Q, He S, Pan H, Liu X, Yuan B, Ding Y, Zhang J (2021) MicroRNA-375: potential cancer suppressor and therapeutic drug. Biosci Rep 41(9):BSR20211494","journal-title":"Biosci Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12426-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12426-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12426-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:16:00Z","timestamp":1788354960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12426-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12426"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12426-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics declaration: Not applicable. This article is a narrative review and does not involve human participants, animal experiments, or clinical interventions.","order":2,"name":"Ethics","label":"Ethics Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1510"}}